منابع مشابه
Hypereosinophilic syndromes
Hypereosinophilic syndromes (HES) constitute a rare and heterogeneous group of disorders, defined as persistent and marked blood eosinophilia (> 1.5 x 10(9)/L for more than six consecutive months) associated with evidence of eosinophil-induced organ damage, where other causes of hypereosinophilia such as allergic, parasitic, and malignant disorders have been excluded. Prevalence is unknown. HES...
متن کاملHow I treat hypereosinophilic syndromes.
Hypereosinophilic syndromes (HESs) are a heterogeneous group of uncommon disorders characterized by marked peripheral eosinophilia and end organ manifestations attributable to the eosinophilia or unexplained in the clinical setting. Whereas corticosteroids remain the mainstay of treatment for most patients, recent diagnostic advances and the development of novel targeted therapies, including ty...
متن کاملHow I Diagnose Hypereosinophilic Syndromes
Hypereosinophilic syndromes are a group of disorders characterised by significant eosinophilia and organ damage. They have proven challenging to define, diagnose, and study for many years, due in part to their variable clinical presentations, the overlap between neoplastic and reactive eosinophilia, and the lack of a universal marker of eosinophil clonality. Herein, we give an overview of the t...
متن کاملClinical and Biological Markers in Hypereosinophilic Syndromes
Hypereosinophilic syndromes (HES) are rare, heterogeneous syndromes characterized by markedly elevated eosinophil counts in the blood and/or tissue and evidence of eosinophil-associated pathology. Although parasitic infections, drug hypersensitivity, and other disorders of defined etiology can present as HES (associated HES), treatment is directed at the underlying cause rather than the eosinop...
متن کاملImatinib mesylate for the treatment of hypereosinophilic syndromes.
Hypereosinophilic syndromes (HES) define several distinct entities, all of which show blood and tissue hypereosinophilia and end-organ secondary manifestations. From a clinical and pathogenic perspective, the best characterized are the myeloproliferative and lymphoproliferative variants. While there are several therapies available for the treatment of HES, such as corticosteroids, IFNalpha and ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Orphanet Journal of Rare Diseases
سال: 2007
ISSN: 1750-1172
DOI: 10.1186/1750-1172-2-37